Ovagen (EDL): Research Overview
Khavinson bioregulator tripeptide studied in liver and gut tissue research.
Also known as EDL · Glu-Asp-Leu
What is Ovagen?
Ovagen is a Khavinson bioregulator tripeptide (EDL) with primary effects on the liver and gastrointestinal tract. Developed by Dr. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it reduces long-term liver fibrosis and protects the GI mucosal layer from antibiotics, environmental toxins, and chemotherapy.
What is Ovagen researched for?
- Reduces long-term fibrosis development in liver tissue.
- Protects liver through gene expression regulation.
- Helps protect GI mucosal layer from various insults.
- May protect GI tract from antibiotic-induced damage.
- Protects against environmental toxin effects on GI tract.
- Addresses age-related liver changes through bioregulation.
- Supports GI tract function during aging.
How does Ovagen work?
Ovagen works through epigenetic regulation by crossing cell and nuclear membranes to directly regulate DNA structure and transcription patterns. It is transported into cells via POT family transporters (PEPT1, PEPT2) that specifically handle di- and tripeptides, explaining its precise tissue targeting.
References
Khavinson Peptide Bioregulators Overview
Advances in Gerontology · 2020
Ovagen (EDL) is a tripeptide bioregulator with effects on liver and GI tract.
POT Family Transporters and
Peptide Bioregulators Drug Metabolism Reviews · 2018
Di- and tripeptides are transported via PEPT1/PEPT2, explaining tissue-specific targeting.
Peptide Bioregulators and
Liver Fibrosis Experimental Gerontology · 2019
Short peptides reduce long-term fibrosis in liver tissue through gene expression regulation.